Dextrose — products, DINs, and Canadian availability
This page lists Health Canada–registered pharmaceutical products whose active ingredient list includes Dextrose. We track 120 distinct Drug Identification Numbers (DINs) for this molecule, of which 18 are currently in marketed status. Across those registrations there are 15 manufacturers or marketing authorization holders, 2 dosage forms, and 38 distinct strength presentations.
Procurement teams normally arrive here for one of three reasons: a specific brand is unavailable and an equivalent registration is needed; a clinical protocol requires a comparator containing Dextrose in a defined strength; or a pharmacy needs to know which manufacturers still hold an active Canadian registration before committing to a substitution. The table below answers the first question directly. For the second and third, Nexara Health can confirm live availability, remaining shelf life, and landed cost from Canadian stock or from any of more than 40 regulated international source markets.
Registration status is not the same as availability. A product can hold marketed status in the Drug Product Database and still be on allocation, discontinued by the holder, or unavailable in the pack size a hospital needs. Where a Dextrose product is in shortage, our Canadian drug shortage tracker carries the reported status, the reason where the manufacturer has published one, and the marketed alternatives sharing the same active ingredient.
Dosage forms and strengths recorded for Dextrose
Dosage forms: Solution, Liquid. Strengths: 3.3 G, 5 G, 4 MG, 10 %, 10 G, 100 MG, 13.3 G, 25 G, 170 MG, 137.5 MG, 200 MG, 20 G, 33.3 MG, 33.3 G.
Manufacturers and marketing authorization holders
BAXTER CORPORATION, B. BRAUN MEDICAL INC, HOSPIRA HEALTHCARE ULC, BAXTER CORPORATION CLINTEC NUTRITION DIVISION, CRITERION SCIENCES, CLINTEC NUTRITION COMPANY, ICU MEDICAL CANADA INC, FRESENIUS KABI CANADA LTD, SMITHS MEDICAL CANADA LTD., DRAXIMAGE A DIVISION OF DRAXIS SPECIALTY PHARMACEUTICALS INC, BDH INC., GENPHARM ULC, WESTERN DIALYSIS SUPPLIES LTD., VANTIVE ULC, ALTHIN BIOPHARM INC..
Registered products containing Dextrose
| DIN | Product | Manufacturer | Strength | Dosage form | Status |
|---|---|---|---|---|---|
| 00438014 | (20 MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP | BAXTER CORPORATION | 3.3 G | Solution | Marketed |
| 00786292 | (20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP | BAXTER CORPORATION | 5 G | Solution | Marketed |
| 00438049 | (20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP | BAXTER CORPORATION | 5 G | Solution | Marketed |
| 00503142 | (20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.2% SODIUM CHLORIDE INJECTION USP | BAXTER CORPORATION | 5 G | Solution | Cancelled Post Market |
| 00437999 | (20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | BAXTER CORPORATION | 5 G | Solution | Marketed |
| 00438030 | (40 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP | BAXTER CORPORATION | 5 G | Solution | Marketed |
| 00438022 | (40MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP | BAXTER CORPORATION | 3.3 G | Solution | Marketed |
| 00438006 | (40MMOL/L)POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | BAXTER CORPORATION | 5 G | Solution | Marketed |
| 01931741 | 0.15% POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.30% SODIUM CHLORIDE INJECTION | B. BRAUN MEDICAL INC | 3.3 G | Solution | Cancelled Post Market |
| 01931598 | 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP | B. BRAUN MEDICAL INC | 5 G | Solution | Marketed |
| 01931601 | 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.33% SODIUM CHLORIDE INJECTION USP | B. BRAUN MEDICAL INC | 5 G | Liquid | Cancelled Post Market |
| 01931547 | 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION | B. BRAUN MEDICAL INC | 5 G | Solution | Cancelled Post Market |
| 01931644 | 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION | B. BRAUN MEDICAL INC | 5 G | Solution | Cancelled Post Market |
| 01931539 | 0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP | B. BRAUN MEDICAL INC | 5 G | Solution | Cancelled Post Market |
| 01967770 | 0.30% POTASSIUM CHLORIDE IN 5% DEXTROSE | B. BRAUN MEDICAL INC | 5 G | Liquid | Cancelled Post Market |
| 01931571 | 0.30% POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION | B. BRAUN MEDICAL INC | 5 G | Solution | Cancelled Post Market |
| 00828602 | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION | BAXTER CORPORATION | 4 MG | Solution | Marketed |
| 00478288 | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | HOSPIRA HEALTHCARE ULC | 4 MG | Solution | Cancelled Post Market |
| 01924249 | 10% DEXTRAN 40 IN 5% DEXTROSE INJECTION | B. BRAUN MEDICAL INC | 10 % | Solution | Cancelled Post Market |
| 01927922 | 10% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP | B. BRAUN MEDICAL INC | 10 G | Solution | Cancelled Post Market |
| 01924427 | 10% DEXTROSE INJECTION USP | B. BRAUN MEDICAL INC | 100 MG | Solution | Marketed |
| 00060364 | 10% DEXTROSE INJECTION, USP | BAXTER CORPORATION | 10 G | Solution | Marketed |
| 02014823 | 10% DEXTROSE INJECTION, USP | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 10 G | Solution | Cancelled Post Market |
| 02003694 | 100GM GLUCOSE TOLERANCE DRINK | CRITERION SCIENCES | 10 G | Liquid | Cancelled Post Market |
| 02015072 | 13.3% DEXTROSE INJECTION, USP | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 13.3 G | Solution | Cancelled Post Market |
| 02143267 | 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 10 G | Solution | Cancelled Post Market |
| 02013975 | 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE CLINIMIX | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 10 G | Solution | Cancelled Post Market |
| 02014106 | 2.5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 10% DEXTROSE QUICKMIX | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 10 G | Solution | Cancelled Post Market |
| 02143259 | 2.5%TRAVASOL AMINO ACID INJ.W.ELEC.W.25%DEX | CLINTEC NUTRITION COMPANY | 25 G | Liquid | Cancelled Post Market |
| 02143232 | 2.75% TRAVAS. AMINO ACID INJ.W.ELECW.25%DEX | CLINTEC NUTRITION COMPANY | 25 G | Liquid | Cancelled Post Market |
| 02014009 | 2.75% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 25% DEXTROSE QUICKMIX | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 170 MG | Solution | Cancelled Post Market |
| 02013991 | 2.75% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 5% DEXTROSE QUICKMIX | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 5 G | Solution | Cancelled Post Market |
| 02143240 | 2.75%TRAVASOL AMINO ACID INJ.W.ELEC.W.5%DEX. | CLINTEC NUTRITION COMPANY | 137.5 MG | Liquid | Cancelled Post Market |
| 01924257 | 20% DEXTROSE INJECTION USP | B. BRAUN MEDICAL INC | 200 MG | Solution | Cancelled Post Market |
| 02015080 | 20% DEXTROSE INJECTION, USP | BAXTER CORPORATION | 20 G | Solution | Cancelled Post Market |
| 01927981 | 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP | B. BRAUN MEDICAL INC | 3.3 G | Solution | Dormant |
| 00038881 | 3.33% DEXTROSE AND 0.3% SODIUM CHLORIDE | ICU MEDICAL CANADA INC | 33.3 MG | Solution | Cancelled Post Market |
| 02014831 | 33.3% DEXTROSE INJECTION, USP | BAXTER CORPORATION | 33.3 G | Solution | Cancelled Post Market |
| 02013908 | 4.25% AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE QUICKMIX | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 20 G | Solution | Cancelled Post Market |
| 02142414 | 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 10 G | Solution | Cancelled Post Market |
| 02142406 | 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 20% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 20 G | Solution | Cancelled Post Market |
| 02014033 | 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 20% DEXTROSE QUICKMIX | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 20 G | Solution | Cancelled Post Market |
| 02142392 | 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 25% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 25 G | Solution | Cancelled Post Market |
| 02014017 | 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 5% DEXTROSE QUICKMIX | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 5 G | Solution | Cancelled Post Market |
| 02142317 | 4.25% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTRLYTES IN 10% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 10 G | Solution | Cancelled Post Market |
| 02142309 | 4.25% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 20 G | Solution | Cancelled Post Market |
| 02142295 | 4.25% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 25% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 25 G | Solution | Cancelled Post Market |
| 02013894 | 4.25% TRAVASOL AMINO ACID WITHOUT ELECTROLYTES IN 5% DEXTROSE QUICKMIX | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 5 G | Solution | Cancelled Post Market |
| 02142325 | 4.25%TRAV. AMINO ACID INJ.W.O.ELECT.5%DEXT. | CLINTEC NUTRITION COMPANY | 5 G | Liquid | Cancelled Post Market |
| 02143224 | 4.25%TRAVASOL AMINO ACID INJ.W.ELECW.5%DEX. | CLINTEC NUTRITION COMPANY | 5 G | Liquid | Cancelled Post Market |
| 01947230 | 40% DEXTROSE INJECTION USP | B. BRAUN MEDICAL INC | 40 % | Solution | Cancelled Post Market |
| 02014858 | 40% DEXTROSE INJECTION, USP | BAXTER CORPORATION | 40 G | Solution | Cancelled Post Market |
| 01927558 | 5% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP | B. BRAUN MEDICAL INC | 5 G | Solution | Dormant |
| 00038873 | 5% DEXTROSE AND 0.225% SODIUM CHLORIDE | ICU MEDICAL CANADA INC | 50 MG | Solution | Cancelled Post Market |
| 00038903 | 5% DEXTROSE AND 0.45% SODIUM CHLORIDE | ICU MEDICAL CANADA INC | 50 MG | Solution | Dormant |
| 01927531 | 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP | B. BRAUN MEDICAL INC | 5 G | Solution | Marketed |
| 00038946 | 5% DEXTROSE AND 0.9% SODIUM CHLORIDE | ICU MEDICAL CANADA INC | 50 MG | Solution | Dormant |
| 01924435 | 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP | B. BRAUN MEDICAL INC | 50 MG | Solution | Marketed |
| 01931652 | 5% DEXTROSE IN LACTATED RINGER'S INJECTION | B. BRAUN MEDICAL INC | 5 G | Solution | Cancelled Post Market |
| 02403536 | 5% DEXTROSE INJECTION | FRESENIUS KABI CANADA LTD | 50 MG | Solution | Marketed |
| 01924281 | 5% DEXTROSE INJECTION USP | B. BRAUN MEDICAL INC | 50 MG | Solution | Marketed |
| 00060348 | 5% DEXTROSE INJECTION, USP | BAXTER CORPORATION | 5 G | Solution | Marketed |
| 02142368 | 5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 20% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 20 G | Solution | Cancelled Post Market |
| 02142252 | 5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 20 G | Solution | Cancelled Post Market |
| 02142244 | 5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 25% DEXTROSE | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 25 G | Solution | Cancelled Post Market |
| 02231257 | 5% XYLOCAINE MPF WITH GLUCOSE 7.5% INJECTION | SMITHS MEDICAL CANADA LTD. | 5 % | Liquid | Cancelled (Unreturned Annual) |
| 01924273 | 50% DEXTROSE INJECTION USP | B. BRAUN MEDICAL INC | 500 MG | Solution | Cancelled Post Market |
| 02014866 | 50% DEXTROSE INJECTION, USP | BAXTER CORPORATION | 50 G | Solution | Cancelled Post Market |
| 02003651 | 50GM GLUCOSE TOLERANCE DRINK | CRITERION SCIENCES | 5 G | Liquid | Cancelled Post Market |
| 02014874 | 70% DEXTROSE INJECTION USP | BAXTER CORPORATION | 70 G | Solution | Marketed |
| 02516179 | 70% DEXTROSE INJECTION USP | B. BRAUN MEDICAL INC | 70 G | Solution | Approved |
| 01924265 | 70% DEXTROSE INJECTION USP | B. BRAUN MEDICAL INC | 70 G | Solution | Cancelled Pre Market |
| 02003643 | 75GM GLUCOSE TOLERANCE DRINK | CRITERION SCIENCES | 7.5 G | Liquid | Cancelled Post Market |
| 00108081 | A-C-D SOLUTION | DRAXIMAGE A DIVISION OF DRAXIS SPECIALTY PHARMACEUTICALS INC | 132 MG | Liquid | Cancelled Post Market |
| 02179075 | ACETATE CONCENTRATE R07376 | BDH INC. | 204.5 G | Liquid | Cancelled Post Market |
| 02231082 | ACID CONCENTRATE (R04146) | GENPHARM ULC | 184 G | Liquid | Cancelled Post Market |
| 00897787 | ACID CONCENTRATE (R04938) | GENPHARM ULC | 172.2 G | Liquid | Cancelled Post Market |
| 00896969 | ACID CONCENTRATE (R04981) | GENPHARM ULC | 180.8 G | Liquid | Cancelled Post Market |
| 00897833 | ACID CONCENTRATE (R04984) | GENPHARM ULC | 172.2 G | Liquid | Cancelled Post Market |
| 02241924 | ACID CONCENTRATE (RO4147) | GENPHARM ULC | 182.9 G | Liquid | Cancelled Post Market |
| 02241925 | ACID CONCENTRATE (RO4148) | GENPHARM ULC | 184.0 G | Liquid | Cancelled Post Market |
| 00898430 | ACID CONCENTRATE (RO9503) | GENPHARM ULC | 214.8 G | Liquid | Cancelled Post Market |
| 02238182 | ACID CONCENTRATE (RZ262C) | GENPHARM ULC | 276.1 G | Liquid | Cancelled Post Market |
| 02238177 | ACID CONCENTRATE (RZ271C) | GENPHARM ULC | 262.98 G | Liquid | Cancelled Post Market |
| 02238178 | ACID CONCENTRATE (RZ272C) | GENPHARM ULC | 262.98 G | Liquid | Cancelled Post Market |
| 02238180 | ACID CONCENTRATE (RZ274C) | GENPHARM ULC | 274.81 G | Liquid | Cancelled Post Market |
| 02238181 | ACID CONCENTRATE (RZ275C) | GENPHARM ULC | 262.98 G | Liquid | Cancelled Post Market |
| 00774243 | ACID CONCENTRATE 2100 | BAXTER CORPORATION | 263 G | Solution | Cancelled Post Market |
| 00774790 | ACID CONCENTRATE 2101 | BAXTER CORPORATION | 263 G | Solution | Cancelled Post Market |
| 00774804 | ACID CONCENTRATE 2102 | BAXTER CORPORATION | 263 G | Solution | Cancelled Post Market |
| 00774839 | ACID CONCENTRATE 2105 | BAXTER CORPORATION | 262.98 G | Liquid | Cancelled Post Market |
| 02239609 | ACID CONCENTRATE 2106 | BAXTER CORPORATION | 263 G | Liquid | Cancelled Post Market |
| 00801712 | ACID CONCENTRATE 2112 | WESTERN DIALYSIS SUPPLIES LTD. | 262.98 G | Liquid | Cancelled Post Market |
| 02210037 | ACID CONCENTRATE 2113 | BAXTER CORPORATION | 263 G | Solution | Cancelled Post Market |
| 00774936 | ACID CONCENTRATE 2116 | BAXTER CORPORATION | 263 G | Solution | Cancelled Post Market |
| 00774944 | ACID CONCENTRATE 2117 | BAXTER CORPORATION | 263 G | Solution | Cancelled Post Market |
| 02239483 | ACID CONCENTRATE 2119 | BAXTER CORPORATION | 263 G | Liquid | Cancelled Post Market |
| 00774960 | ACID CONCENTRATE 2120 | BAXTER CORPORATION | 263 G | Solution | Cancelled Post Market |
| 00774979 | ACID CONCENTRATE 2121 | BAXTER CORPORATION | 268.24 G | Solution | Cancelled Post Market |
| 02237690 | ACID CONCENTRATE 2122 | BAXTER CORPORATION | 263 G | Solution | Cancelled Post Market |
Sourcing Dextrose through a licensed wholesaler
Nexara Health imports and distributes under Health Canada Drug Establishment Licence #3-002896. For Dextrose we can quote Canadian-marketed presentations, equivalent registrations from the EU, UK, US, Switzerland, Australia, and Japan where the Canadian presentation is unavailable, and comparator-grade supply with Certificate of Analysis, batch and expiry records, and full chain of custody for clinical trial use. Cold-chain presentations ship under GDP conditions with continuous temperature monitoring.
Request a quote
Nexara Health is a Health Canada–licensed pharmaceutical wholesaler (DEL #3-002896) based in Winnipeg, Manitoba, supplying hospitals, pharmacies, clinics, CROs, and trial sponsors across Canada. Send us the product, strength, presentation, and quantity for Dextrose and we will come back with availability, source market, lead time, and landed cost — usually within 24 hours.
Request a sourcing quote or call +1 (431) 588-9055.